Maksim Mamonkin

Maksim Mamonkin

Auto-generated profile, based on publicly available information

Maksim Mamonkin

Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children’s Hospital and Houston Methodist Hospital, Houston, Texas, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2016 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
MHMeenakshi Hegde
Meenakshi Hegde
MMMalini Mukherjee
Malini Mukherjee
ZGZakaria Grada
Zakaria Grada
APAntonella Pignata
Antonella Pignata
DLDaniel Landi
Daniel Landi
NANabil Ahmed
Nabil Ahmed
In preclinical models of glioblastoma, antigen escape variants can lead to tumor recurrence after treatment with CAR T cells that are redirected to single tumor antigens. Given the heterogeneous expression of antigens on glioblastomas, we hypothesized that a bispecific CAR molecule would mitigate antigen escape and improve the antitumor activity of T cells. Here, we created a CAR that joins a HER2-binding scFv and an IL13Rα2-binding IL-13 mutein to make a tandem CAR exodomain (TanCAR) and a CD28.ζ endodomain. We determined that patient TanCAR T cells showed distinct binding to HER2 or IL13Rα2 and had the capability to lyse autologous glioblastoma. TanCAR T cells exhibited activation dynamics that were comparable to those of single CAR T cells upon encounter of HER2 or IL13Rα2. We observed that TanCARs engaged HER2 and IL13Rα2 simultaneously by inducing HER2-IL13Rα2 heterodimers, which promoted superadditive T cell activation when both antigens were encountered concurrently. TanCAR T cell activity was more sustained but not more exhaustible than that of T cells that coexpressed a HER2 CAR and an IL13Rα2 CAR, T cells with a unispecific CAR, or a pooled product. In a murine glioblastoma model, TanCAR T cells mitigated antigen escape, displayed enhanced antitumor efficacy, and improved animal survival. Thus, TanCAR T cells show therapeutic potential to improve glioblastoma control by coengaging HER2 and IL13Rα2 in an augmented, bivalent immune synapse that enhances T cell functionality and reduces antigen escape.

20 July 2017 in Blood
Verified
Journal Article
Open access
PDF file
DGDiogo Gomes-Silva
Diogo Gomes-Silva
MSMadhuwanti Srinivasan
Madhuwanti Srinivasan
SSSandhya Sharma
Sandhya Sharma
CLCiaran M. Lee
Ciaran M. Lee
DWDimitrios L. Wagner
Dimitrios L. Wagner
MMMaksim Mamonkin
Maksim Mamonkin
Key Points: Genomic disruption of CD7 prior to CAR transduction allows generation of CD7 CAR T cells without extensive self-antigen-driven fratricide. CD7 CAR T cells have robust activity against T-cell malignancies in vitro and in vivo.

20 August 2015 in Blood
Verified
Journal Article
Open access
PDF file
MMMaksim Mamonkin
Maksim Mamonkin
RRRayne H. Rouce
Rayne H. Rouce
HTHaruko Tashiro
Haruko Tashiro
MBMalcolm K. Brenner
Malcolm K. Brenner
Key Points: T cells transduced with a CD5 CAR demonstrate limited and transient fratricide and expand ex vivo. CD5 CAR T cells eliminate T-ALL blasts in vitro and control disease progression in xenograft T-ALL mouse models.

1 October 2017 in Cell Reports
Verified
Journal Article
Open access
DGDiogo Gomes-Silva
Diogo Gomes-Silva
MMMalini Mukherjee
Malini Mukherjee
MSMadhuwanti Srinivasan
Madhuwanti Srinivasan
GKGiedre Krenciute
Giedre Krenciute
ODOlga Dakhova
Olga Dakhova
MMMaksim Mamonkin
Maksim Mamonkin
Antigen-independent tonic signaling by chimeric antigen receptors (CARs) can increase differentiation and exhaustion of T cells, limiting their potency. Incorporating 4-1BB costimulation in CARs may enable T cells to resist this functional exhaustion; however, the potential ramifications of tonic 4-1BB signaling in CAR T cells remain unclear. Here, we found that tonic CAR-derived 4-1BB signaling can produce toxicity in T cells via continuous TRAF2-dependent activation of the nuclear factor κB (NF-κB) pathway and augmented FAS-dependent cell death. This mechanism was amplified in a non-self-inactivating gammaretroviral vector through positive feedback on the long terminal repeat (LTR) promoter, further enhancing CAR expression and tonic signaling. Attenuating CAR expression by substitution with a self-inactivating lentiviral vector minimized tonic signaling and improved T cell expansion and anti-tumor function. These studies illuminate the interaction between tonic CAR signaling and the chosen expression platform and identify inhibitory properties of the 4-1BB costimulatory domain that have direct implications for rational CAR design.

13 July 2020 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
FMFeiyan Mo
Feiyan Mo
NWNorihiro Watanabe
Norihiro Watanabe
MMMary K. McKenna
Mary K. McKenna
MHM. John Hicks
M. John Hicks
MSMadhuwanti Srinivasan
Madhuwanti Srinivasan
MMMaksim Mamonkin
Maksim Mamonkin

3 May 2009 in Nature Immunology
Verified
Journal Article
Open access
PDF file
TYTakeshi Yamada
Takeshi Yamada
CPChun Shik Park
Chun Shik Park
MMMaksim Mamonkin
Maksim Mamonkin
HLH Daniel Lacorazza
H Daniel Lacorazza
The transcription factor ELF4 controls hematopoietic stem cell quiescence. Lacorazza and colleagues show that ELF4 is also needed to maintain the quiescence of naive T cells during steady-state conditions and after antigen stimulation. Transcription factors that regulate the quiescence, proliferation and homing of lymphocytes are critical for effective immune system function. Here we demonstrate that the transcription factor ELF4 directly activated the tumor suppressor KLF4 'downstream' of T cell antigen receptor signaling to induce cell cycle arrest in naive CD8+ T cells. Elf4- and Klf4-deficient mice accumulated CD8+CD44hi T cells during steady-state conditions and generated more memory T cells after immunization. The homeostatic population expansion of CD8+CD44hi T cells in Elf4-null mice resulted in a redistribution of cells to nonlymphoid tissue because of lower expression of the transcription factor KLF2 and the surface proteins CCR7 and CD62L. Our work describes the combinatorial effect of lymphocyte-intrinsic factors on the homeostasis, activation and homing of T cells.